CGT4859

Small molecule

CCogent Biosciences, Inc.

CGT4859 is one of 52 small molecule programs targeting Cholangiocarcinoma. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CholangiocarcinomaActive, not recruiting

CholangiocarcinomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

147 competitors in Cholangiocarcinoma

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

22 2

Pemazyre

Incyte

Phase 3

5 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

16 4

Lenvima

Eisai

Phase 3

3 5

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

11 6

Fotivda

Roche

Phase 3

1 7

Alinamin

Roche

Phase 3

1 8

Cotellic

Roche

Phase 3

1 9

Alecensa

Roche

Phase 3

1 10

Perjeta

Roche

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1/2Recruiting

Cholangiocarcinoma

NCT06777316

Clinical

Trials by Indication[1]

Cholangiocarcinoma1 trial

A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

Recruiting·CCogent Biosciences, Inc.·Phase 1/2·NCT06777316·110 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for CGT4859. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CGT4859 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CGT4859. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Cogent Biosciences, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: CCogent Biosciences, Inc.

CGT4859

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Cholangiocarcinoma1 trial

References

Drug Info

Quick Facts

Related News